VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viatris Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.26−0.39 (-2.12%)
Close on Oct 19, 2026
- Market cap
- $21.24B
- P/E (TTM)
- –
- Dividend yield
- 2.63%
Viatris Inc revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Developed Markets Segment | $8.55B | $8.96B | $9.28B | $9.79B | $10.43B | $8.51B | $8.24B | $8.29B | 59.8% | -4.6% |
| Greater China | $2.33B | $2.17B | $2.16B | $2.20B | $2.21B | $259.90M | $214.60M | $168.10M | 16.3% | +7.6% |
| Emerging Markets Segment | $2.22B | $2.26B | $2.56B | $2.64B | $3.14B | $1.85B | $1.72B | $1.68B | 15.5% | -1.9% |
| Japan, Australia and New Zealand Segment | $1.20B | $1.35B | $1.43B | $1.63B | $2.03B | $1.20B | $1.19B | $1.13B | 8.4% | -11.3% |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Developed Markets Segment | – | – | $4.09B | $4.88B | $5.14B | $4.24B | $4.14B | $4.27B | – |
| Greater China | – | – | $1.43B | $1.51B | $1.40B | $52.70M | $89.90M | $71.90M | – |
| Emerging Markets Segment | – | – | $1.09B | $1.21B | $1.40B | $610.40M | $561.90M | $647.40M | – |
| Japan, Australia and New Zealand Segment | – | – | $522.90M | $665.50M | $762.40M | $364.60M | $323.20M | $363.10M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Brands | $9.18B | $9.20B | $9.80B | $9.89B | $10.84B | $5.23B | $5.36B | $5.52B | 64.2% | -0.2% |
| Generics | $5.07B | $5.49B | $5.59B | $6.33B | $6.97B | $5.29B | $4.80B | $5.22B | 35.4% | -7.8% |
| Lipitor | $1.55B | $1.47B | $1.56B | $1.64B | $1.66B | – | – | – | 10.8% | +5.5% |
| Norvasc | $709.90M | $673.30M | $732.40M | $775.10M | $824.70M | – | – | – | 5.0% | +5.4% |
| Lyrica | $487.00M | $495.40M | $556.50M | $623.80M | $728.50M | – | – | – | 3.4% | -1.7% |
| EpiPen Auto-Injectors | $469.70M | $392.00M | $442.20M | $378.00M | $391.70M | – | – | – | 3.3% | +19.8% |
| Viagra | $408.20M | $395.60M | $428.80M | $458.90M | $533.80M | – | – | – | 2.9% | +3.2% |
| Creon | $365.80M | $328.20M | $304.90M | $304.00M | $309.80M | – | – | – | 2.6% | +11.5% |
| Celebrex | $272.90M | $285.60M | $330.60M | $338.10M | $344.40M | – | – | – | 1.9% | -4.4% |
| Yupelri | $266.90M | $238.50M | $220.80M | $202.10M | $161.90M | – | – | – | 1.9% | +11.9% |
| Effexor | $257.70M | $252.90M | $262.90M | $279.60M | $316.80M | – | – | – | 1.8% | +1.9% |
| Zoloft | $254.90M | $235.70M | $235.70M | $246.20M | $284.30M | – | – | – | 1.8% | +8.1% |
| Influvac | $194.40M | $178.70M | $192.40M | $225.50M | $299.30M | – | – | – | 1.4% | +8.8% |
| Dymista | $163.60M | $188.00M | $200.00M | $179.80M | $168.00M | – | – | – | 1.1% | -13.0% |
| Xalabrands | $158.40M | $166.40M | $193.20M | $195.10M | $226.00M | – | – | – | 1.1% | -4.8% |
| Amitiza | $158.10M | $149.20M | $157.00M | $167.90M | $201.50M | – | – | – | 1.1% | +6.0% |
| Xanax | $139.90M | $145.00M | $154.80M | $156.50M | $185.90M | – | – | – | 1.0% | -3.5% |
| Complex GX and Biosimilars | – | – | – | $1.31B | $1.34B | $1.30B | $1.21B | $522.60M | – | – |
| Product and Service, Other | – | – | – | – | – | $126.10M | $130.20M | $165.20M | – | – |
| Net sales | – | – | $15.39B | $16.22B | $17.81B | $11.82B | $11.37B | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.01B | $3.43B | $3.55B | $3.95B | $4.18B | $3.75B | $3.97B | $3.87B | 21.0% | -12.5% |
| China | $2.08B | $1.91B | $1.89B | $1.95B | $1.98B | $216.10M | $171.10M | – | 14.5% | +8.8% |
| India | – | – | – | – | – | $1.16B | $1.17B | $1.16B | – | – |
| France | – | – | – | – | – | $1.07B | $1.05B | $1.09B | – | – |
From the segment and revenue-disaggregation notes of Viatris's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.